Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has been assigned an average rating of “Moderate Buy” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $22.2222.

Several analysts recently commented on the company. Morgan Stanley decreased their price target on Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 12th. JMP Securities reduced their target price on shares of Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Oppenheimer reaffirmed an “outperform” rating and issued a $44.00 target price (down previously from $48.00) on shares of Bicycle Therapeutics in a report on Monday, August 11th. Finally, Royal Bank Of Canada set a $27.00 target price on shares of Bicycle Therapeutics and gave the stock an “outperform” rating in a research report on Monday, August 11th.

Bicycle Therapeutics Stock Up 1.3%

NASDAQ BCYC opened at $6.95 on Wednesday. Bicycle Therapeutics has a twelve month low of $6.10 and a twelve month high of $28.67. The stock has a market cap of $481.70 million, a P/E ratio of -1.98 and a beta of 1.41. The company’s 50-day simple moving average is $7.62 and its 200 day simple moving average is $8.04.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Friday, August 8th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative return on equity of 32.43%. The company had revenue of $2.90 million for the quarter, compared to analyst estimates of $9.43 million. Research analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BCYC. Armistice Capital LLC grew its position in Bicycle Therapeutics by 4.8% during the 2nd quarter. Armistice Capital LLC now owns 2,800,000 shares of the company’s stock worth $19,460,000 after acquiring an additional 128,000 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in Bicycle Therapeutics by 4.6% in the second quarter. Westfield Capital Management Co. LP now owns 2,780,491 shares of the company’s stock worth $19,324,000 after purchasing an additional 123,186 shares in the last quarter. Long Focus Capital Management LLC grew its holdings in shares of Bicycle Therapeutics by 138.2% during the first quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company’s stock worth $10,984,000 after purchasing an additional 750,661 shares during the last quarter. Candriam S.C.A. increased its stake in shares of Bicycle Therapeutics by 10.8% in the first quarter. Candriam S.C.A. now owns 1,205,207 shares of the company’s stock valued at $10,232,000 after buying an additional 117,331 shares in the last quarter. Finally, Tybourne Capital Management HK Ltd. raised its holdings in shares of Bicycle Therapeutics by 72.4% in the second quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock valued at $6,907,000 after buying an additional 417,400 shares during the last quarter. 86.15% of the stock is owned by institutional investors and hedge funds.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.